Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Target Background
CD44v7/8 is another alternative splicing isoform of CD44 originally discovered as the lymphocyte homing receptor, which exists in a large range of isoforms functioning as a receptor for the glycosaminoglycan hyaluronan via variability in the pattern of glycosylation (both N- and O-linked) and of multiple splice variants. Since CD44v6 participates in a wide variety of bioprocesses such as cell-cell interactions, cell adhesion and migration, it involves in multiple cellular functions like lymphocyte activation, recirculation and homing, hematopoiesis, and especially tumor metastasis. Therefore, CD44v7/8 is regarded as a functional biomarker and therapeutic target for CAR-T cell immunotherapy.
Anti-CD44v7/8 CAR-T Cell Therapy
The studies of preclinical and clinical anti-CD44v7/8 CAR-T cell therapy has not been reported up to now. Therefore, Creative Biolabs helps researchers capture the brighter and prosperous future of anti-CD44v7/8 CAR-T cell therapy.
Animal Models for in vivo Study of anti-CD44v7/8 CAR-T Cell Therapy
Creative Biolabs offers researchers almost all the animal models generated from the major techniques including the conventional carcinogen-induced models, the mosaic transposon- or virus-induced models, the transgenic models and the subcutaneous or patient-derived xenograft models for a variety of human malignancies.
Furthermore, Creative Biolabs is always passionate about introducing our well-established animal models to in vivo tests of adoptive cell therapy and providing assistance in creating the most clinically relevant animal models with customized requirements. You request, Creative Biolabs offers the best.
In vivo Assay Parameters and Techniques
At Creative Biolabs, we offer the most exquisite and comprehensive service platform for preclinical CD44v7/8 CAT-T cell therapy research.
Efficacy Test
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking
Viability and Bio-distribution Studies
Durability, bio-distribution studies
Toxicity Evaluation
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
Histopathology
Tumorigenicity study
Creative Biolabs is thrilled to find values in unexpected areas with original heart and innovations to write the CAR-T cell therapy an incredible scientific revolution.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
